[Management of complications in patients with chronic myelogenous leukemia].
Management of complications in patients with chronic myelogenous leukemia(CML) were reviewed. In chronic phase, the complications due to the increased WBC are not common. Currently, most patients are treated with interferon and/or hydroxyurea. Although the clinical benefit of interferon therapy has been proven with randomized trials, side effects with interferon are significantly higher than hydroxyurea. Common side effects are fatigue, weight loss, insomnia, depression and neurotoxicity. The complications following stem cell transplantation are classified into three categories: 1) regimen related toxicities of heart, lung and liver, 2) acute complications related to hematoimmune disturbance including acute and chronic graft-versus-host disease and infectious complications, 3) long term consequences of stem cell transplantation. During blastic phase, management of infectious complications is important.
Yoshida
M
M
Fourth Department of Internal Medicine, Teikyo University School of Medicine.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006086:Graft vs Host Disease / Q000188:drug therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D016867:Immunocompromised Host; D007239:Infections / Q000188:drug therapy* / Q000209:etiology; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000276:immunology / Q000628:therapy; D009503:Neutropenia / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D016898:Interferon-alpha; D006918:Hydroxyurea